Patients with resected stage IIIB-C or stage IV melanoma had better long-term outcomes with nivolumab vs ipilimumab.

On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...

Regorafenib plus nivolumab did not improve survival over chemotherapy in patients with previously treated gastric/GEJ cancer.

The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).

Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...